These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35312337)

  • 61. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
    Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
    [No Abstract]   [Full Text] [Related]  

  • 62. Metabolic parameters of [
    Markus M; Sartor H; Bjurberg M; Trägårdh E
    Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Usefulness of [18F]fluoro-2-deoxy-D-glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors.
    Igai H; Matsuura N; Tarumi S; Chang SS; Misaki N; Go T; Ishikawa S; Yokomise H
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):143-5. PubMed ID: 20951602
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The usefulness of machine-learning-based evaluation of clinical and pretreatment
    Nakajo M; Nagano H; Jinguji M; Kamimura Y; Masuda K; Takumi K; Tani A; Hirahara D; Kariya K; Yamashita M; Yoshiura T
    Br J Radiol; 2023 Sep; 96(1149):20220772. PubMed ID: 37393538
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic Significance of Metabolic Parameters by
    Lee J; Cho YS; Kim J; Shim YM; Lee KH; Choi JY
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572388
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Machine-Learning Approach Using PET-Based Radiomics to Predict the Histological Subtypes of Lung Cancer.
    Hyun SH; Ahn MS; Koh YW; Lee SJ
    Clin Nucl Med; 2019 Dec; 44(12):956-960. PubMed ID: 31689276
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Baseline [
    Yang Q; Luo Y; Zhang Y; Zhang W; Zhou D; Li F
    Eur Radiol; 2022 Aug; 32(8):5568-5576. PubMed ID: 35316362
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preoperative prediction of regional lymph node metastasis of colorectal cancer based on
    He J; Wang Q; Zhang Y; Wu H; Zhou Y; Zhao S
    Ann Nucl Med; 2021 May; 35(5):617-627. PubMed ID: 33738763
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Retrospective analysis of the
    Yang Y; Pan YQ; Wang M; Gu S; Bao W
    Radiat Oncol; 2023 Dec; 18(1):196. PubMed ID: 38049843
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Utility of pre-treatment 18 F-fluorodeoxyglucose PET radiomic analysis in assessing nodal involvement in cervical cancer.
    Chan KC; Perucho JAU; Subramaniam RM; Lee EYP
    Nucl Med Commun; 2023 May; 44(5):375-380. PubMed ID: 36826394
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prediction of Chemotherapy Response of Osteosarcoma Using Baseline
    Jeong SY; Kim W; Byun BH; Kong CB; Song WS; Lim I; Lim SM; Woo SK
    Contrast Media Mol Imaging; 2019; 2019():3515080. PubMed ID: 31427908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 76. (18)Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography total glycolytic volume in thymic epithelial neoplasms evaluation: a reproducible image biomarker.
    Bertolaccini L; Viti A; Lanzi E; Fortunato M; Chauvie S; Bianchi A; Terzi A
    Gen Thorac Cardiovasc Surg; 2014 Apr; 62(4):228-33. PubMed ID: 24477745
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Correlation of
    Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The maximal contrast-enhanced range of CT for differentiating the WHO pathological subtypes and risk subgroups of thymic epithelial tumors.
    Yu C; Li T; Yang X; Xin L; Zhao Z; Yang Z; Zhang R
    Br J Radiol; 2023 Oct; 96(1150):20221076. PubMed ID: 37486626
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Usefulness of Preoperative
    Ishibashi M; Tanabe Y; Yunaga H; Miyoshi H; Miwa K; Nakamura H; Fujii S; Ogawa T
    Yonago Acta Med; 2019 Mar; 62(1):146-152. PubMed ID: 30962757
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.